Literature DB >> 11999904

Prevalence of smoking in psychiatric patients.

Marie-France Poirier1, Olivier Canceil, Franck Baylé, Bruno Millet, Marie-Chantal Bourdel, Cécile Moatti, Jean-Pierre Olié, Dominique Attar-Lévy.   

Abstract

Compelling evidence that tobacco-smoking is a form of drug addiction exists. The aim of this study is to determine the following: (1) prevalence of tobacco-smoking and of nicotine dependence in French psychiatric patients; (2) rates and patterns of tobacco smoking and of nicotine dependence according to diagnosis; (3) relationship between current smoking status and antipsychotic medications; and (4) relationship between cigarette smoking and neurological side effects induced by neuroleptics. A population of 711 psychiatric in- and outpatients was assessed using: (1) a detailed smoking self-questionnaire for smoking history and nicotine dependence; and (2) a questionnaire for staff covering treatments and DSMIII-R diagnoses. Data were analyzed using chi2 analysis of variance (ANOVA) tests (one factor) for quantitative comparisons between groups of patients, and analysis of covariance (ANCOVA) test with age covariate was performed for age-dependent variables. Prevalence of smoking in the population of psychiatric patients was significantly higher than in the French general population. Diagnoses among current smokers were mainly substance-related disorder and schizophrenia. The authors established correlations between prevalence of smoking and age, sex, marital and socioeconomic status, alcohol use, coffee consumption and other psychoactive substance use or abuse. The authors did not find relationship between smoking prevalence and institutionalization. Neuroleptic neurological side effects were significantly fewer among smokers compared to nonsmokers. However, the rate of smokers was significantly higher in psychiatric patients receiving neuroleptic drugs. Nicotine abuse in psychiatric patients, and especially in schizophrenic patients, could support the hypothesis that smoking is consistent with self-medication.

Entities:  

Mesh:

Year:  2002        PMID: 11999904     DOI: 10.1016/s0278-5846(01)00304-9

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  31 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  How is tobacco treatment provided during drug treatment?

Authors:  Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann; Kimber P Richter
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

4.  Understanding the drug treatment community's ambivalence towards tobacco use and treatment.

Authors:  Kimber P Richter; Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann
Journal:  Int J Drug Policy       Date:  2012-01-26

5.  Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study.

Authors:  Marja-Leena Mattila; Tuula Hurtig; Helena Haapsamo; Katja Jussila; Sanna Kuusikko-Gauffin; Marko Kielinen; Sirkka-Liisa Linna; Hanna Ebeling; Risto Bloigu; Leena Joskitt; David L Pauls; Irma Moilanen
Journal:  J Autism Dev Disord       Date:  2010-09

6.  Addressing nicotine dependence in psychodynamic psychotherapy: perspectives from residency training.

Authors:  Judith J Prochaska; Sebastien C Fromont; Peter Banys; Stuart J Eisendrath; Mardi J Horowitz; Marc H Jacobs; Sharon M Hall
Journal:  Acad Psychiatry       Date:  2007 Jan-Feb

Review 7.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

8.  Staff commitment to providing tobacco dependence in drug treatment: Reliability, validity, and results of a national survey.

Authors:  Jamie J Hunt; A Paula Cupertino; Byron J Gajewski; Yu Jiang; Telmo M Ronzani; Kimber P Richter
Journal:  Psychol Addict Behav       Date:  2013-10-14

Review 9.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

10.  Smoking and mental illness: results from population surveys in Australia and the United States.

Authors:  David Lawrence; Francis Mitrou; Stephen R Zubrick
Journal:  BMC Public Health       Date:  2009-08-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.